Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem DTwP-HepB-Hib) in Uniject With Quinvaxem Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age

Next Previous
Trial Profile

A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem DTwP-HepB-Hib) in Uniject With Quinvaxem Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-DTP-hepatitis B vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Crucell

Most Recent Events

  • 12 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 06 Feb 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
  • 05 Sep 2013 Planned end date changed from 1 Sep 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top